Navigation Links
TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
Date:7/14/2008

HOUSTON, TX Scientists from The University of Texas M. D. Anderson Cancer Center have found overexpression of tissue type transglutaminase (TG2) in ovarian cancer is associated with increased tumor cell growth and adhesion, resistance to chemotherapy and lower overall survival rates. When researchers targeted and silenced TG2 in animal models, cancer progression was reversed, suggesting the protein may also provide a novel therapeutic approach for late-stage ovarian cancer.

These findings in the July 15th issue of Cancer Research by a team of researchers led by Anil K. Sood, M.D., professor in the Departments of Gynecologic Oncology and Cancer Biology, and Kapil Mehta, Ph.D., professor in the Department of Experimental Therapeutics at M. D. Anderson, are among the first to explore TG2's functionality in ovarian cancer.

"TG2 appears to fuel different types of cancer through multiple molecular pathways, making it an important therapeutic target," said Mehta, whose lab also has connected TG2 overexpression to drug-resistant and metastatic melanoma, breast cancer and pancreatic cancer.

"Drug resistance and metastasis are major impediments to the successful treatment of ovarian cancer and until now we had little information about the role TG2 played in ovarian cancer," Sood said. "We began to see its story unfold as we translated this data from tissue samples to cell lines to animal models."

The American Cancer Society estimates 15,000 U.S. women will die from ovarian cancer this year. Most patients present with advanced stage disease that has spread beyond the primary tumor site. More than 70 percent of ovarian cancer patients will suffer a recurrence and eventually succumb to the disease.

Higher TG2, lower survival

The study, which examined 93 ovarian cancer samples of ranging stages, found that high levels of TG2 corresponded with significantly lower patient survival than those with lo
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New study shows greenback cutthroat trout involved in recovery effort misidentified
2. Brain network related to intelligence identified
3. The reservoir of Marburg virus identified in a species of fruit bat
4. Genes that both extend life and protect against cancer identified
5. Genes identified to protect brassicas from damaging disease
6. Newly-identified exercise gene could help with depression
7. Best treatment identified to reduce deadly Staph infections
8. New approach for attacking lupus identified
9. Mutant gene identified as villain in hardening of the arteries
10. Cognitive, genetic clues identified in imaging study of alcohol addiction
11. Novel mechanism for long-term learning identified by Carnegie Mellon researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions , ... entire spectrum of clinical research, is proud to announce ... company,s comprehensive SaaS-based eClinical technology platform, has led the ... first two quarters of 2015.   Q2 2015 and ... quarters measured by contract value sold in the company,s ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
(Date:8/6/2015)... , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking Integration ... Moverio BT-200 see-through head mounted display and on SMI,s ... quality and efficiency is brought to personalized visualization and ... first time, professionals and researchers can integrate gaze, and ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... milk can kill cancer cells, reveal studies carried out by ... Although the special substance, known as HAMLET (Human ... milk several years ago, it is only now that it ... cancer of the bladder who were treated with the substance ...
... a new species of dinosaur with a softball-sized lump of ... paper published in the April issue of the journal ... dinosaur about as big as a medium-sized dog that lived ... Yale University, lead author of the paper. The team discovered ...
... TALLAHASSEE, Fla. - Imagine the marriage of hard metals or ... wonderful offspring hybrid materials never conceived by Mother Nature. ... says biologist Steven Lenhert, the newest faculty face of nanoscience ... mobile phone fitted with a "lab on a chip" that ...
Cached Biology News:New bony-skulled dinosaur species discovered in Texas 2Bionanotechnology has new face, world-class future at Florida State 2Bionanotechnology has new face, world-class future at Florida State 3
(Date:8/31/2015)... Aug. 31, 2015 Trimb Healthcare AB ("Trimb") ... acquire YouMedical Group BV ("YouMedical"), a Dutch OTC company ... annual sales of approximately EUR 16 million, with solid ... "Our ambition is to build a leading international ... toward that goal. YouMedical gives us a stronger North ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
(Date:8/28/2015)... 2015 Research and Markets ... "Global & USA BioSimilar Market Analysis to 2021" ... awaited US Biosimilar market will be initiated in September ... How will the global market react? Will biosimilars explode ... could save the US economy up to $250 billion ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... has organized and will present a session on chemical spectroscopic imaging at JASIS ... and exposition is Asia’s largest analytical and scientific instruments show which will be ...
Breaking Biology Technology:U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3
... YORK, June 18 Danube Pharmaceuticals, Inc., a,privately ... development of innovative drugs for ophthalmology, is pleased,to ... MBA as its Chief,Executive Officer., "I am ... this,inflection point in its history as it advances ...
... CHESHIRE, Conn., June 18 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... Officer of Alexion Pharmaceuticals, will present at the,Jefferies & ... at 4:15,p.m., ET on Wednesday, June 25, 2008., ... available live. You can,access the webcast at: http://www.alexionpharm.com ...
... N.J., June 18 HemoCue(R) AB, a,global point-of-care ... Diagnostics Incorporated (NYSE: DGX ), today announced,that ... quantitative point-of-care,test for screening for, diagnosing and monitoring ... U.S. Food and Drug Administration (FDA). With,the FDA ...
Cached Biology Technology:Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5
... Hitachi Innovative Linear Ion Trap Time of Flight Mass Analyzer for ... mode measurement range: 100 - 25,000 m/z, * Precursor ion selection ... over, * MS accuracy: 5 ppm with internal reference, * Dynamic ... ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... series combines Harvard Apparatuss best pump mechanism, a ... range of configuration options. A lookup table in ... from all the major manufacturers. A bright, two ... information from across the lab. All models have ...
Biology Products: